A new $1 billion fund backed by 20 drugmakers including Merck & Co. Inc. and Pfizer Inc. is aiming to bolster struggling antibiotic companies and sustain a pipeline for new treatments.
Finch Therapeutics reported positive topline results from PRISM3, a Phase II trial of CP101, an oral microbiome drug for the prevention of recurrent C. difficile infection.
Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported.
A COVID-19 vaccine candidate under development by China’s CanSino Biologics is moving forward in development after the company published data supporting patient safety.
Foster City, California-based SutroVax closed on a Series D preferred stock financing worth $110 million, which was co-led by new investors RA Capital Management and Janus Henderson Investors.
A lot of attention shifted to the malaria drug hydroxychloroquine for treatment of COVID-19, the disease caused by the novel coronavirus.
Big pharma has largely gotten out of the antibiotics business, with about 90 percent of research on new antibiotics being conducted by small biotech companies with market caps of less than $100 million, more than half pre-revenue.
BioSpace reviews some of the more interesting scientific studies recently published.
Melinta Therapeutics filed for bankruptcy protection, becoming the latest casualty of a persistent cash burn in the antibiotic industry.
Iterum Therapeutics reported topline results from the SURE 3 Phase III clinical trial of an oral and intravenous penem antibiotic.